Discussing Baricitinib for Alopecia Areata

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Amy McMichael, MD

Key Takeaways

Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Inflammatory cytokines like IFN-γ and TNF-α are key contributors to immune-mediated hair follicle destruction.
The chronicity of alopecia areata is linked to persistent immune dysregulation and genetic predisposition.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment for severe alopecia areata (AA).

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Common Comorbidities Associated With Alopecia Areata

EP: 3.Epidemiology Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

Now Viewing

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

Video content above is prompted by the following:

McMichael: Baricitinib became the first systemic treatment for severe AA after the BRAVE-AA1 and BRAVE-AA2 phase 3 trials were released. What did the data show in terms of safety and efficacy that led to FDA approval in 2022?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!